The Food and Drug Administration issued a Complete Response Letter to Eli Lilly & Co. (NYSE: LLY) and Incyte Corp. (Nasdaq: INCY) for their moderate-to-severe rheumatoid arthritis treatment. Shares of Eli Lilly plunged $3.50 to close at $82.38 while Incyte stock plummeted $14.77 to close at $126.07.
